SerpinA3k Deficiency Ameliorates Experimental type 2 Diabetes

Area of Science:

• Biochemistry
• Metabolic Diseases
• Endocrinology

Background:

• Type 2 diabetes (T2D) is a global health issue exacerbated by obesity and leading to severe complications.
• Serpins are protease inhibitors; SerpinA3k is a mouse homolog of human SerpinA3.
• SerpinA3k influences angiogenesis, ROS, inflammation, and fibrosis, but its role in renal damage, obesity, and T2D is unclear.

Purpose of the Study:

• To investigate the impact of SerpinA3k deficiency on obesity and T2D-associated metabolic dysfunctions.
• To explore SerpinA3k as a potential therapeutic target for T2D.

Main Methods:

• Wild-type (WT) and SerpinA3k knockout (KO) male mice were fed standard (SD) or high-fat diets (HFD).
• A subset of HFD mice received streptozotocin to induce T2D (D2).
• Metabolic parameters, pancreatic function, adipose tissue, and renal function were assessed after 27 weeks.

Main Results:

• Diabetic WT mice showed hyperglycemia, hyperinsulinemia, increased fat tissue, and renal hyperfiltration.
• Diabetic SerpinA3k KO mice were protected, exhibiting improved glycemic control, higher pancreatic insulin, reduced insulin resistance, and better adipocyte remodeling.
• KO mice also demonstrated preserved lipolytic function and attenuated renal hyperfiltration.

Conclusions:

• SerpinA3k deficiency mitigates hyperglycemia and insulin resistance in a T2D model.
• Preserving adipose tissue functionality and preventing metabolic complications are linked to SerpinA3k absence.
• SerpinA3k emerges as a promising therapeutic target for T2D and related metabolic disorders.